In Segment C, individuals will get ABBV-744 and oral navitoclax. In Section D, members will obtain ABBV-744 and ruxolitinib. Individuals will acquire treatment until finally disorder progression or maybe the contributors are unable to tolerate the study drugs. Celastrol was determined being a Myb inhibitor that suppressed C/EBPβ exercise and https://abbv-744-cancer-treatment02457.onesmablog.com/considerations-to-know-about-abbv-744-brd4-inhibitor-cancer-therapy-efficacy-72588898